Ivermectin in COVID-19
These pages contain the scientific rationale that justifies the use of ivermectin in COVID-19.
We regard ivermectin as a core medication in the prevention and treatment of COVID-19. For comprehensive information on ivermectin please refer to our Review of the Emerging Evidence Supporting the Use of Ivermectin in the Prophylaxis and Treatment of COVID-19 and the included references.
The Safety of Ivermectin – High Doses
Many have questions about the safety of higher doses of this medicine for treatment after exposure or in-hospital critical care circumstances. See our Ivermectin Safety Overview.
For PATIENTS AND RELATIVES, please review our GUIDE FOR YOU. It tells how to find physicians who prescribe ivermectin as well as provides information to share with your primary care physician in the event that he or she is not aware of the current evidence detailing how safe and effective ivermectin is in preventing and treating all stages of COVID-19 and all variants of the SARS-CoV-2 virus.
Ivermectin is a well-known, FDA-approved anti-parasite drug that has been used successfully for more than four decades to treat onchocerciasis “river blindness” and other parasitic diseases. It is one of the safest drugs known. It is on the WHO’s list of essential medicines, has been given 3.7 billion times around the globe, and has won the Nobel prize for its global and historic impacts in eradicating endemic parasitic infections in many parts of the world. Our medical discovery of a rapidly growing published medical evidence base, demonstrating ivermectin’s unique and highly potent ability to inhibit SARS-CoV-2 replication and to suppress inflammation, prompted our team to use ivermectin for prevention and treatment in all stages of COVID-19. Ivermectin is not yet FDA-approved for the treatment of COVID-19, but on Jan 14, 2021, the NIH changed their recommendation for the use of ivermectin in COVID-19 from “against” to “neutral”. (see our press release).
In March 2020 we created our life-saving MATH+ Hospital Treatment Protocol for COVID-19, which is intended for hospitalized patients. In October 2020 we developed the I-MASK+ Prophylaxis & Early Outpatient Treatment Protocol for COVID-19, which is designed for use as a prophylaxis and in early outpatient treatment, for those who test positive for COVID-19. The protocols complement each other, and both are physiologic-based combination treatment regimens developed by leaders in critical care medicine. All the component medicines are FDA-approved, inexpensive, readily available and have been used for decades with well-established safety profiles. Both protocols are available in several languages.
More recent studies and clinical trials on ivermectin
August 26, 2021 | Cureus
“Ivermectin as a SARS-CoV-2 Pre-Exposure Preventive in Healthcare Workers: a Propensity Score-Matched Retrospective Cohort Study”
a study from doctors who continued to use ivermectin to subdue COVID-19 with great success in the Dominican Republic.
IVM as a Covid Pre-Exposure Preventive.
June 15, 2021 | J Antibiot (Tokyo)
“The mechanisms of action” of Ivermectin against SARS-CoV-2: An evidence-based clinical review article.” reports overwhelmingly positive data for ivermectin’s use in the pandemic.
“100% of 36 early treatment and prophylaxis studies report positive effects… using the most serious outcome reported 79% and 85% improvement for early treatment and prophylaxis respectively…Statistically significant improvements were seen for mortality, ventilation, hospitalization, cases, and viral clearance…100% of the 17 Randomized Controlled Trials (RCTs) for early treatment and prophylaxis report positive effects, with an estimated improvement of 73% and 83% respectively, and 93% of all 28 RCTs.)… The consistency of positive results across a wide variety of cases has been remarkable. It is extremely unlikely that the observed results could have occurred by chance.”
Favorable outcome on viral load and culture viability using Ivermectin in early treatment of non-hospitalized patients with mild COVID-19 – A double-blind, randomized placebo-controlled trial can be found at the following link: https://www.medrxiv.org/content/10.1101/2021.05.31.21258081v1
For an up-to-date overview of all published studies on ivermectin in the treatment and prevention of COVID-19 we recommend visiting c19ivermectin.com; in addition, a meta-analysis of all studies can be found at ivmmeta.com (constantly updated).
A majority of the studies (until January 12, 2021) were included in our comprehensive Review of the Emerging Evidence Supporting the Use of Ivermectin in the Prophylaxis and Treatment of COVID-19, and a brief summary of the studies at that time can be found in the accompanying One-page summary of the scientific review on ivermectin.
Update: The FLCCC Alliance’s “Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19” has been peer-reviewed, accepted, and published on May 1, 2021, in the American Journal of Therapeutics!
- Our comprehensive review of the emerging evidence for ivermectin use in our I-MASK+ protocol
- A “Summary of the Evidence for Ivermectin in COVID-19”
- Dr. Paul Marik’s comprehensive meta-analysis of COVID-19 therapeutics
- An introductory video explaining the review on ivermectin by Dr. Pierre Kory
- A lecture on I-MASK+ by Dr. Paul Marik
- Invited Grand Rounds Lecture on ivermectin by Pierre Kory
- An FLCCC Alliance guide to the management of COVID-19 by Dr. Paul Marik
Please also regard our Videos & Tutorials section.